全文获取类型
收费全文 | 11161篇 |
免费 | 862篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 56篇 |
儿科学 | 296篇 |
妇产科学 | 148篇 |
基础医学 | 1449篇 |
口腔科学 | 195篇 |
临床医学 | 1282篇 |
内科学 | 1820篇 |
皮肤病学 | 157篇 |
神经病学 | 1538篇 |
特种医学 | 713篇 |
外科学 | 1214篇 |
综合类 | 160篇 |
一般理论 | 11篇 |
预防医学 | 1198篇 |
眼科学 | 280篇 |
药学 | 808篇 |
中国医学 | 21篇 |
肿瘤学 | 692篇 |
出版年
2022年 | 64篇 |
2021年 | 151篇 |
2020年 | 90篇 |
2019年 | 136篇 |
2018年 | 175篇 |
2017年 | 130篇 |
2016年 | 176篇 |
2015年 | 207篇 |
2014年 | 239篇 |
2013年 | 340篇 |
2012年 | 488篇 |
2011年 | 511篇 |
2010年 | 327篇 |
2009年 | 272篇 |
2008年 | 486篇 |
2007年 | 520篇 |
2006年 | 498篇 |
2005年 | 513篇 |
2004年 | 502篇 |
2003年 | 469篇 |
2002年 | 474篇 |
2001年 | 254篇 |
2000年 | 355篇 |
1999年 | 317篇 |
1998年 | 223篇 |
1997年 | 167篇 |
1996年 | 200篇 |
1995年 | 153篇 |
1994年 | 136篇 |
1993年 | 149篇 |
1992年 | 215篇 |
1991年 | 215篇 |
1990年 | 288篇 |
1989年 | 212篇 |
1988年 | 218篇 |
1987年 | 191篇 |
1986年 | 169篇 |
1985年 | 184篇 |
1984年 | 148篇 |
1983年 | 128篇 |
1982年 | 113篇 |
1981年 | 122篇 |
1980年 | 92篇 |
1979年 | 94篇 |
1978年 | 93篇 |
1977年 | 67篇 |
1976年 | 59篇 |
1975年 | 70篇 |
1974年 | 54篇 |
1968年 | 55篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
12.
Costs and benefits of routine follow-up after curative treatment for endometrial cancer 总被引:6,自引:0,他引:6 下载免费PDF全文
OBJECTIVE: To examine the costs of routine outpatient follow-up after curative treatment of endometrial cancer, and to determine whether this leads to early detection of recurrence or survival. The impact of specific disease characteristics on survival is examined. DESIGN: Retrospective chart review, and calculation of costs. SETTING: Ottawa Regional Cancer Centre-Civic Division (ORCC-C). PATIENTS: All 432 patients referred to the ORCC-C with endometrial cancer between 1982 and 1991 who received treatment with curative intent and who continued with routine follow-up. RESULTS: Cancer recurred in 50 patients (11.57%). There was no statistically significant difference in overall survival between patients with symptomatic and asymptomatic recurrences, or between those with recurrences detected during routine follow-up visits or in the interval between routine visits. Of 4830 Papanicolaou (Pap) smears performed routinely, cancer was detected in 6 cases. The mean cost of the routine follow-up procedures for each patient with a recurrence was $19,200. CONCLUSION: Intensive follow-up of women with endometrial cancer does not result in improved survival. A prospective randomized study is warranted to evaluate other potential benefits of follow-up, such as improved quality of life or decreased morbidity. There is no economic or clinical justification for the routine use of the Pap smear in the follow-up of patients with endometrial cancer. The potential benefits of routine follow-up in endometrial cancer and other types of cancer with favourable prognoses warrant critical evaluation. 相似文献
13.
Perry Guaglianone Kenneth Chan Eduardo DelaFlor-Weiss Rosemarie Hanisch Susan Jeffers Desh Sharma Franco Muggia 《Investigational new drugs》1994,12(2):103-110
Summary We have completed a phase I and pharmacology study of liposomally-encapsulated daunorubicin (DaunoXome). Of 32 patients entered, 30 were evaluable. No toxicity was encountered at the initial doseescalation steps from 10 to 60 mg/m2. At 80 mg/m2, two patients manifested grade 2 neutropenia. At least grade 3 neutropenia occurred in all patients receiving 120 mg/m2. Alopecia and subjective intolerance were mild. Cardiotoxicity was not observed except for an episode of arrhythmia in a patient with lung cancer and prior radiation. Only one minor objective response was observed in this population of refractory solid tumors. Pharmacokinetics differed from those of the free drug with no detection of daunorubicinol. We recommend future phase II studies with a dose of 100 mg/m2 in previously treated and 120 mg/m2 of DaunoXome in previously untreated patients with solid tumors.EDW is supported in part by ACS award 92-14-1 相似文献
14.
15.
16.
The techniques specific to peroperative fluorocholangiography are discussed based on an experience of 632 cholangiograms and an estimation has been made of the associated radiation doses to staff and patients. Rapid and accurate information can be obtained during fluorocholangiography using appropriate techniques with acceptably low radiation hazards. 相似文献
17.
Perry D. Cohen Linda Herman Sheryl Jedlinski Peggy Willocks Paula Wittekind 《Neurotherapeutics》2007,4(3):537-544
A patient-centered paradigm for clinical research and medical care is presented as a solution to the problem of declining
innovation and increasing costs and development time in the pipeline for new therapies. Fundamental differences in values
and motivations among scientists, clinicians, industry sponsor, and patients in neurotherapeutics provide a framework for
analysis of ethical conflicts and the loss of public confidence in medical research. Parkinson advocates’ views on clinical
trial participation, perceived risks and benefits, placebo controls, and sham surgery are presented. These views reflect the
sense of urgency and the unique perspective that comes from living with this progressive, debilitating condition full time.
A patient-centered paradigm that includes authentic voices of patients as collaborators at every stage of development will
help to resolve conflicts, build trust, recruit trial participants, and accelerate new therapies. Key elements are adaptive
clinical trial methods and the development of information technology for the assessment of outcomes and surveillance of safety
over the life cycle of a medical product. Supported by the Parkinson’s Disease Foundation, the Parkinson Pipeline Project
is a grassroots group of Parkinson’s patients whose goal is to represent an authentic voice for patients in the treatment
development process. This group promotes education and communication between members of the Parkinson’s community and active
stakeholders in medical research, industry, and regulatory agencies. Its members are an example of a new breed of knowledgeable
consumers, armed with first-hand access to research findings and reinforced by on-line connections to like-minded peers throughout
the world. 相似文献
18.
19.
20.
M. L. Margallo-Lana P. B. Moore D. W. K. Kay R. H. Perry B. E. Reid T. P. Berney & S. P. Tyrer 《Journal of intellectual disability research : JIDR》2007,51(6):463-477
Background The clinical and neuropathological features associated with dementia in Down’s syndrome (DS) are not well established. Aims To examine clinico‐pathological correlations and the incidence of cognitive decline in a cohort of adults with DS. Method A total of 92 hospitalized persons with DS were followed up from 1985 to December 2000. At outset, 87 participants were dementia‐free, with a median age of 38 years. Assessments included the Prudhoe Cognitive Function Test (PCFT) and the Adaptive Behavior Scale (ABS), to measure cognitive and behavioural deterioration. Dementia was diagnosed from case records and caregivers’ reports. Results Eighteen (21%) patients developed dementia during follow‐up, with a median age of onset 55.5 years (range 45–74). The PCFT demonstrated cognitive decline among those with a less severe intellectual disability (mild and moderate) but not among the profoundly disabled people (severe and profound). Clinical dementia was associated with neuropathological features of Alzheimer’s disease, and correlated with neocortical neurofibrillary tangle densities. At the age of 60 years and above, a little more than 50% of patients still alive had clinical evidence of dementia. Conclusions Clinical dementia associated with measurable cognitive and functional decline is frequent in people with DS after middle age, and can be readily diagnosed among less severely intellectually disabled persons using measures of cognitive function such as the PCFT and behavioural scales such as the ABS. In the more profoundly disabled people, the diagnosis of dementia is facilitated by the use of behavioural and neurological criteria. In this study, the largest prospective DS series including neuropathology on deceased patients, the density of neurofibrillary tangles related more closely to the dementia of DS than senile plaques. In people with DS surviving to middle and old age, the development of dementia of Alzheimer type is frequent but not inevitable, and some people with DS reach old age without clinical features of dementia. 相似文献